Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)-Reference-Cited by-同舟云学术

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Published:2022-05-01 Issue:5 Volume:8 Page:717
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kehl Kenneth L.¹,Zahrieh David²,Yang Ping²,Hillman Shauna L.²,Tan Angelina D.²,Sands Jacob M.¹,Oxnard Geoffrey R.¹,Gillaspie Erin A.³,Wigle Dennis²,Malik Shakun⁴,Stinchcombe Thomas E.⁵,Ramalingam Suresh S.⁶,Kelly Karen⁷,Govindan Ramaswamy⁸,Mandrekar Sumithra J.²,Osarogiagbon Raymond U.⁹,Kozono David¹

Affiliation:

1. Dana-Farber/Partners CancerCare, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts

2. Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota

3. Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee

4. National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Maryland

5. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina

6. The Winship Cancer Institute of Emory University, Atlanta, Georgia

7. University of California at Davis Comprehensive Cancer Center, Sacramento

8. Alvin J Siteman Cancer Center and Washington University School of Medicine, St Louis, Missouri

9. Baptist Cancer Center, Memphis, Tennessee

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2790373/jamaoncology_kehl_2022_oi_220002_1652478708.79534.pdf

Reference43 articles.

1. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer.;Ginsberg;Ann Thorac Surg,1995

2. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent.;Smeltzer;JAMA Oncol,2018

3. Survival after mediastinal node dissection, systematic sampling, or neither for early stage NSCLC.;Ray;J Thorac Oncol,2020

4. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.;Pignon;J Clin Oncol,2008

5. Quality measures in clinical stage I non-small cell lung cancer: improved performance is associated with improved survival.;Samson;Ann Thorac Surg,2017

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma;JAMA Oncology;2024-08-01

2. Induction therapy for non–small cell lung cancer;The Journal of Thoracic and Cardiovascular Surgery;2024-08

3. A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection;BMC Pulmonary Medicine;2024-07-10

4. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis;Cancers;2024-07-08

5. Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer;American Society of Clinical Oncology Educational Book;2024-06